Selective activation of p38 mitogen-activated protein (MAP) kinase isoforms by the MAP kinase kinases MKK3 and MKK6

UMMS Affiliation

Hughes Medical Institute, Program in Molecular Medicine

Publication Date


Document Type



Amino Acid Sequence; Antibodies, Monoclonal; Calcium-Calmodulin-Dependent Protein Kinases; Cloning, Molecular; Enzyme Activation; Enzyme Inhibitors; Humans; Imidazoles; Isoenzymes; MAP Kinase Kinase 3; MAP Kinase Kinase 6; *Mitogen-Activated Protein Kinase Kinases; *Mitogen-Activated Protein Kinases; Molecular Sequence Data; Phosphorylation; Protein-Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyridines; p38 Mitogen-Activated Protein Kinases


Life Sciences | Medicine and Health Sciences


The cellular response to treatment with proinflammatory cytokines or exposure to environmental stress is mediated, in part, by the p38 group of mitogen-activated protein (MAP) kinases. We report the molecular cloning of a novel isoform of p38 MAP kinase, p38 beta 2. This p38 MAP kinase, like p38 alpha, is inhibited by the pyridinyl imidazole drug SB203580. The p38 MAP kinase kinase MKK6 is identified as a common activator of p38 alpha, p38 beta 2, and p38 gamma MAP kinase isoforms, while MKK3 activates only p38 alpha and p38 gamma MAP kinase isoforms. The MKK3 and MKK6 signal transduction pathways are therefore coupled to distinct, but overlapping, groups of p38 MAP kinases.

DOI of Published Version



J Biol Chem. 1998 Jan 16;273(3):1741-8.

Journal/Book/Conference Title

The Journal of biological chemistry

Related Resources

Link to Article in PubMed

PubMed ID